Literature DB >> 25380163

Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria: an operational cohort study.

Marleen E Hendriks1, Oladimeji A Bolarinwa, Ferdinand W N W Wit, Lizzy M Brewster, Aina O Odusola, Nicole T A Rosendaal, Navin R Bindraban, Peju Adenusi, Kayode Agbede, Joep M A Lange, Tanimola M Akande, Constance Schultsz.   

Abstract

OBJECTIVE: To assess the feasibility of providing guideline-based cardiovascular disease (CVD) prevention care within the context of a community-based health insurance program (CBHI) in rural Nigeria.
METHODS: A prospective operational cohort study was conducted in a primary healthcare clinic in rural Nigeria, participating in a CBHI program. The insurance program provided access to care and improved the quality of the clinics participating in the program, including CVD prevention guideline implementation. Insured adults at risk of CVD were consecutively included upon clinic attendance. The primary outcome was quality of care determined by scoring of quality indicators on patient files of the cohort, 1.5 year after guideline implementation.
RESULTS: Of the 368 screened patients, 349 were included and 323 (93%) completed 1 year of follow-up. The majority of patients (331, 95%) had hypertension. Process indicators showed that 114/115 (99%) new hypertension cases had a record of CVD risk assessment and 249/333 (75%) eligible cases a record of lifestyle advice. Outcome indicators showed that in 292/328 (64%) hypertension cases, blood pressure was on target. Barriers to care included limited human resources, limited affordability of diagnostic tests and multidrug regimes for the healthcare provider, frequent doctor's appointments, and inefficient drug supplies.
CONCLUSION: Implementation of CVD prevention care within the context of a CBHI program resulted in high-quality care in rural sub-Saharan Africa, comparable to high-income countries. However, guideline implementation was resource-intense and specific recommendations were not feasible. Simple models of care delivery are needed for rapid scale-up of CVD prevention services in sub-Saharan Africa.

Entities:  

Mesh:

Year:  2015        PMID: 25380163     DOI: 10.1097/HJH.0000000000000401

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Prevalence of hypertension and blood pressure profile amongst urban-dwelling adults in Nigeria: a comparative analysis based on recent guideline recommendations.

Authors:  Njideka U Okubadejo; Obianuju B Ozoh; Oluwadamilola O Ojo; Ayesha O Akinkugbe; Ifedayo A Odeniyi; Oluseyi Adegoke; Babawale T Bello; Osigwe P Agabi
Journal:  Clin Hypertens       Date:  2019-04-15

Review 2.  Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review.

Authors:  Carla Castillo-Laborde; Macarena Hirmas-Adauy; Isabel Matute; Anita Jasmen; Oscar Urrejola; Xaviera Molina; Camila Awad; Catalina Frey-Moreno; Sofia Pumarino-Lira; Fernando Descalzi-Rojas; Tomás José Ruiz; Barbara Plass
Journal:  Public Health Rev       Date:  2022-09-02

3.  Association of the variants and haplotypes in the DOCK7, PCSK9 and GALNT2 genes and the risk of hyperlipidaemia.

Authors:  Tao Guo; Rui-Xing Yin; Wei-Xiong Lin; Wei Wang; Feng Huang; Shang-Ling Pan
Journal:  J Cell Mol Med       Date:  2015-10-23       Impact factor: 5.310

4.  Enablers and barriers for implementing high-quality hypertension care in a rural primary care setting in Nigeria: perspectives of primary care staff and health insurance managers.

Authors:  Aina O Odusola; Karien Stronks; Marleen E Hendriks; Constance Schultsz; Tanimola Akande; Akin Osibogun; Henk van Weert; Joke A Haafkens
Journal:  Glob Health Action       Date:  2016-02-12       Impact factor: 2.640

Review 5.  Interventions targeting hypertension and diabetes mellitus at community and primary healthcare level in low- and middle-income countries:a scoping review.

Authors:  Jorge César Correia; Sarah Lachat; Grégoire Lagger; François Chappuis; Alain Golay; David Beran
Journal:  BMC Public Health       Date:  2019-11-21       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.